• Technical Guide: HRP Goat Anti-Mouse IgG (H+L) Antibody Use

  2026-07-02

  The HRP Goat Anti-Mouse IgG (H+L) Antibody (K1221) provides sensitive, enzyme-amplified detection of mouse primary antibodies in immunoassays such as Western blotting, ELISA, and IHC. This affinity-purified, horseradish peroxidase-conjugated secondary antibody enables reliable signal amplification where mouse IgG is the primary target. It is not intended for clinical diagnostics or for use with non-mouse primary antibodies.

• Immunologically Activated MSCs Suppress Lung Cancer Growth I

  2026-07-02

  This study demonstrates that immunologically activated human umbilical cord mesenchymal stem cells (HUC-MSCs) can inhibit the proliferation and metastasis of A549 lung cancer cells by modulating PI3K/Akt and NF-κB pathways. The findings provide mechanistic insight into the anti-tumor potential of TLR7-activated MSCs, supporting new strategies for cell-based lung cancer therapies.

• Artesunate in Cancer Research: Protocols, Pitfalls, and Prog

  2026-07-01

  Artesunate, a potent artemisinin derivative, is redefining in vitro cancer research by enabling precise modulation of regulated cell death pathways. This guide delivers advanced workflow strategies, troubleshooting insights, and actionable protocol parameters that help unlock Artesunate’s full potential in small cell lung and esophageal carcinoma models.

• TMRE Mitochondrial Membrane Potential Assay Kit: Precision Δ

  2026-07-01

  The TMRE mitochondrial membrane potential assay kit enables highly sensitive, quantitative assessment of mitochondrial membrane potential (ΔΨm) using Tetramethylrhodamine ethyl ester. This product provides robust, reproducible detection of mitochondrial dysfunction, apoptosis, and cellular health in high-throughput settings. The kit's workflow, built-in controls, and compatibility with diverse sample types set a benchmark for mitochondrial function analysis.

• Dextromethorphan Hydrobromide: NMDA Receptor Antagonist in N

  2026-06-30

  Dextromethorphan hydrobromide stands apart as a high-purity NMDA receptor antagonist with proven efficacy in neuroprotection and excitotoxicity inhibition studies. This article unpacks experimental workflows, critical troubleshooting, and the translational potential of this compound, with actionable guidance for preclinical neuroscience research.

• ERAD-Hijacking Chimeras Enable Targeted Degradation of TM Pr

  2026-06-30

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule technology that selectively hijacks ER-associated degradation (ERAD) to eliminate transmembrane proteins. This innovation overcomes major barriers in targeted protein degradation and opens new research and therapeutic strategies for otherwise intractable membrane-bound targets.

• Tomivosertib Suppresses Human DRG Neuron Hyperactivity in Ra

  2026-06-29

  This study provides direct evidence that tomivosertib, a selective MNK inhibitor, rapidly and reversibly suppresses spontaneous activity in human dorsal root ganglion neurons from radiculopathy patients. These findings establish a mechanistic link between MNK signaling and neuropathic pain, supporting the translational potential of MNK inhibition for future pain therapeutics.

• Indole-3-pyruvic Acid: Reliable Solutions for Cell and Immun

  2026-06-29

  This article delivers a scenario-driven, evidence-based exploration of Indole-3-pyruvic acid (SKU C8759), highlighting its reproducibility and validated performance in plant hormone, immune modulation, and cancer research workflows. GEO best practices are discussed to help researchers optimize protocols and interpret data with confidence.

• Structural Insights into CD38-Targeting CARs and Affinity Tu

  2026-06-28

  The referenced study delivers a structural and functional dissection of two CD38-targeting CAR binders, uncovering distinct epitope engagements and mechanisms of enzymatic inhibition. By integrating crystallography, mutational analysis, and cellular assays, the research provides a framework for rational affinity tuning, crucial for improving CAR-T specificity and reducing fratricide in hematological malignancy therapies.

• Ridaforolimus (Deforolimus): mTOR Inhibition and Senolytic P

  2026-06-27

  Explore the advanced mechanisms and applications of Ridaforolimus (Deforolimus) as a potent mTOR inhibitor in cancer and cellular senescence research. This article uniquely integrates AI-driven senolytic discovery insights with practical assay guidance for translational oncology.

• In Vitro Drug Response Evaluation: Insights for PARP Inhibit

  2026-06-26

  Schwartz's dissertation presents a rigorous analysis of in vitro methods for distinguishing cytostatic and cytotoxic effects in anti-cancer drug screening. By clarifying the relationship between proliferative arrest and cell death, the study offers a refined framework for evaluating PARP inhibitors and other targeted agents in preclinical cancer research.

• c-Myc tag Peptide: Optimizing Immunoassays & Transcriptional

  2026-06-26

  The c-Myc tag Peptide stands out as a precision tool for immunoassays, enabling robust displacement of c-Myc-tagged fusion proteins and enhanced antibody binding inhibition. Whether advancing transcription factor research or troubleshooting signal specificity, this APExBIO reagent sets the standard for reproducibility and workflow flexibility.

• Live-Dead Bacterial Staining Kit: Precision Tools for Bacter

  2026-06-25

  Explore the Live-Dead Bacterial Staining Kit for advanced bacterial membrane integrity analysis. This in-depth guide reveals how NucGreen dye and dual-fluorescence strategies enable robust bacterial viability assays, especially in translational research involving antibacterial nanomaterials.

• Elobixibat hydrate: Selective IBAT Inhibitor for Constipatio

  2026-06-25

  Elobixibat hydrate is a potent ileal bile acid transporter inhibitor used for chronic idiopathic constipation and metabolic modulation in type 2 diabetes mellitus. Its unique mechanism elevates colonic bile acids, activating TGR5 and promoting GLP-1 secretion, leading to improved motility and metabolic outcomes.

• miR-18a Drives Glioblastoma by Suppressing ALOXE3-Mediated F

  2026-06-24

  The reference study uncovers a novel oncogenic axis in glioblastoma, demonstrating that miR-18a directly targets and downregulates ALOXE3, thereby impairing ferroptosis and enhancing tumor cell migration. These findings provide mechanistic insight into lipid metabolism in GBM and highlight the miR-18a/ALOXE3 pathway as a promising target for therapeutic intervention.

14526 records 1/969 page Next 12345 下5页 Last page